Gimv continues to increase its presence in German-speaking Europe Gimv continues to increase its presence in German-speaking Europe Gimv continues to increase its presence in German-speaking Europe
Gimv continues to increase its presence in German-speaking Europe
Expansion of Life Science department in German-speaking Europe Annegret de Baey-Diepolder joins partner team
Gimv, the pan-European investment company, is focussing on expanding its investment business in German-speaking Europe as well as its expertise in the Life Sciences sector. With qualified doctor Annegret de Baey-Diepolder on board as a partner the company has gained a reputable expert from the Venture Capital and Life Sciences field.
Annegret de Baey-Diepolder (41) began her professional career as a physician at the Klinik für Dermatologie und Allergologie (clinic for Dermatology and Allergology) of the Munich University. As part of her academic career she took on a Postdoctoral Fellowship at the Institut für Immunologie (institute for Immunology), owned by the company Hoffmann La Roche. In 1999 she started as a Senior Research Group Leader at Micromet AG before moving in 2001 to TVM Capital as an associate where she was appointed a partner in 2006. During her time at TVM she was involved in the Intercell, Jerini, Medigene PIPE and Riemser Arzneimittel AG transactions to name but a few. She also had seats on the supervisory boards of Vivendy, Albireo Pharma and Nitec.
“With Annegret de Baey-Diepolder on board Gimv has gained an Investment Manager who brings with her a vast wealth of experience in the medical, biotechnology and investment sectors”, says Patrick Van Beneden, Executive Vice President Life Sciences at Gimv, “and she’ll strengthen our investment activities in these areas throughout all financing phases”.
With its international team Gimv currently has stakes in 20 companies in the Life Sciences sector and is growing rapidly. In the Benelux countries Gimv is already the number 1 in the Life Sciences division. In Germany, Gimv has just invested EUR 19 million in a second financing round in the consortium in JenaValve, a medical-technical company. Patrick Van Beneden still sees “great growth potential” in the German-speaking region.
Annegret de Baey-Diepolder shall conduct her business from the Munich site. “This enables us to continue increasing our local presence in the German-speaking investment market and focus on the Cleantech and Technology divisions which are important to Gimv too”, concludes Alex Brabers, Executive Vice President at Gimv.